Advertisement

Acta Neurochirurgica

, Volume 126, Issue 2–4, pp 63–71 | Cite as

High sensitivity of the in vivo detection of somatostatin receptors by111Indium (DTPA-octreotide)-scintigraphy in meningioma patients

  • G. Hildebrandt
  • K. Scheidhauer
  • C. Luyken
  • H. Schicha
  • N. Klug
  • P. Dahms
  • B. Krisch
Clinical Articles

Summary

The recent availability of isotope-labelled somatostatin analogues has allowed one to detect somatostatin receptors in normal tissue as well as in endocrine or non-endocrine cranial tumours. The purpose of the present study was to establish the value of somatostatin receptor scintigraphy using an111Indium-labelled somatostatin analogue, octreotide, in the diagnostic work-up of meningioma patients.

Twenty-two patients (16 women, 6 men, aged from 19–70 years) with newly diagnosed, residual or recurrent cranial meningiomas were examined.111Indium-labelled DTPA-octreotide was injected i.V., Planar and tomographic images were obtained with a gamma camera 4–6, and 24 hours after injection. In all of the meningiomas studied a high density of somatostatin receptors was detected by scintigraphy. No false negative test result was found. Due to this, a 100% predictive value of a negative test was calculated. However, when the tumours were taken in culture differing staining intensity could be seen in the light- and electron microscopic level even on individual cells of a single culture when silver intensified somatostatin-gold was used as ligand.

We conclude, that in vivo somatostatin receptor scintigraphy may aid in the pre-operative differential diagnosis of skull base tumours.

Keywords

Somatostatin receptor 111Indium-labelled somatostatin analogue scintigraphy meningioma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Al-Mefty O, Ayoubi S, Smith RR (1991) Direct surgery of the cavernous sinus: patient selection. Acta Neurochir (Wien) [Suppl] 53: 117–121Google Scholar
  2. 2.
    Bakker WH, Albert R, Bruns C, Breemann WAP, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP (1991) [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radio-labelling and in vitro validation. Life Sci 49: 1583–1591PubMedGoogle Scholar
  3. 3.
    Bakker WH, Krenning EP, Reubi JC, Breeman WAP, Setyono-Han B, de Jong M, Kooij PPM, Bruns C, van Hagen PH, Marbach P, Visser TJ, Pless J, Lamberts SWJ (1991) In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 49: 1593–1601PubMedGoogle Scholar
  4. 4.
    Black BK, Kernohan JW (1950) Primary diffuse tumors of the meninges (so-called meningeal menigiomatosis). Cancer 3: 805–819PubMedGoogle Scholar
  5. 5.
    Blankenstein MA, van der Meulen-Dijk C, Thijssen JHH (1987) Assay of oestrogen and progestin receptors in human meningioma cytosols using immunological methods. Clin Chim Acta 165: 189–195PubMedGoogle Scholar
  6. 6.
    Boggan J (1992) Reviewer's comments. Skull Base Surg 2: 133Google Scholar
  7. 7.
    Brazeau P, Vale W, Burgus R, Leug N, Butcher M, Rivier J, Guillemin R (1972) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone secretion. Science 129: 77–79Google Scholar
  8. 8.
    Canalis E (1992) Clinical review 35. Growth factors and their potential clinical value. J Clin Endocrinol Metab 75: 1–4PubMedGoogle Scholar
  9. 9.
    Donnell MS, Meyer GA, Donegan WL (1979) Estrogen-receptor protein in intracranial meningiomas. J Neurosurg 50: 499–502PubMedGoogle Scholar
  10. 10.
    Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F, Sara R, Bonnio C, Lunghi F (1991) In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I] SDZ 204-090). J Clin Endocrinol Metab 73: 850–856PubMedGoogle Scholar
  11. 11.
    Galen RS, Gambino SR (1975) Beyond normality. The predictive value and efficiency of medical diagnoses. Wiley, New York, p 209Google Scholar
  12. 12.
    Golnik KC, Miller NR, Long DM (1992) Rate of progression and severity of neuro-ophthalmologic manifestations of cavernous sinus meningiomas. Skull Base Surg 2: 129–133Google Scholar
  13. 13.
    Greenberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russel CP, Lucci L, Stevenson LL (1991) Treatment of unresectable meningiomas with the anti-progesterone agent mifepristone. J Neurosurg 74: 861–866PubMedGoogle Scholar
  14. 14.
    Hildebrandt G, Zierski J, Csecsei G, Mueller HW, Stracke H (1992) Results of continuous long term intravenous application of octreotide via an implantable pump system in acromegaly resistent to operative and X-ray therapy. Acta Neurochir (Wien) 117: 160–165Google Scholar
  15. 15.
    Joseph K, Stapp J, Reinecke J, Höffken H, Benning R, Neuhaus C, Trautmann HE, Schwerk WB, Arnold R (1992) Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren. Dtsch Med Wschr 117: 1025–1028PubMedGoogle Scholar
  16. 16.
    Koper W, Markstein R, Kohler C, Kwekkeboom DJ, Avezaat JJ, Lamberts SWJ, Reubi JC (1992) Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab 74: 543–547PubMedGoogle Scholar
  17. 17.
    Krenning EP, Bakker WH, Breemann WAP, Koper JW, Kooij PPM, Ausema L, Lameris JS, Reubi JC, Lamberts SWJ (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet i: 242–244Google Scholar
  18. 18.
    Krisch B, Buchholz C, Mentlein R (1991) Somatostatin binding sites on rat diencephalic astrocytes. Light-microscopic study in vitro and in vivo. Cell Tissue Res 263: 253–263PubMedGoogle Scholar
  19. 19.
    Krisch B, Buchholz C, Mentlein R, Turzynski A (1993) Visualization of neuropeptide binding sites on individual telencephalic neurons. Cell Tissue Res: in pressGoogle Scholar
  20. 20.
    Kwekkeboom DJ, Krenning EP, Lamberts SWJ (1991) Clinically nonfunctioning pituitary adenomas: in vivo receptor imaging and in vitro hormone responses. In: Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (eds) Pituitary adenomas: new trends in basic and clinical research. Elsevier, Amsterdam, pp 359–364Google Scholar
  21. 21.
    Lamberts SWJ, Krenning EP, Bakker WH, Breeman WAP, Kooij PPM, Reubi JC (1991) Somatostatin receptor imaging in the diagnosis of pituitary and parasellar tumors. In: Melmed S, Robbins RJ (eds) Molecular and clinical advances in pituitary disorders. Blackwell, Oxford, pp 285–292Google Scholar
  22. 22.
    Lamberts SWJ, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev 12: 450–482Google Scholar
  23. 23.
    Lamberts SWJ, Koper JW, Reubi JC, Krenning EP (1992) Endocrine aspects of diagnosis and treatment of primary brain tumours. Clin Endocrinol 37: 1–10Google Scholar
  24. 24.
    Larson JJ, Tew JM, Wiot JG, Courten-Myers GM (1992) Association of meningiomas with dural “tails”; surgical significance. Acta Neurochir (Wien) 114: 59–63Google Scholar
  25. 25.
    Markwalder T-M, Waelti ER (1991) Endocrine manipulation of meningiomas with medroxyprogesterone acetate. In: Paoletti P, Takakura K, Walker MD, Butti G, Pezzotta S (eds) Neurooncology. Kluwer, Dordrecht, pp 267–273Google Scholar
  26. 26.
    Martuza RL, Ojemann RG (1982) Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment. Neurosurgery 10: 1–12PubMedGoogle Scholar
  27. 27.
    Mentlein R, Buchholz C, Krisch B (1989) Binding and internalization of gold-conjugated somatostatin and growth hormone-releasing hormone in cultured rat somatotropes. Cell Tissue Res 258: 309–317PubMedGoogle Scholar
  28. 28.
    Mentlein R, Buchholz C, Krisch B (1990) Somatostatin-binding sites on rat telencephalic astrocytes. Light- and electron-microscopic study in vitro and in vivo. Cell Tissue Res 262: 431–443PubMedGoogle Scholar
  29. 29.
    Ojemann RG (1992) Skull-base surgery: a perspective. J Neurosurg 76: 569–570PubMedGoogle Scholar
  30. 30.
    Perrot-Applanat M, Groyer-Picard MTh, Kujas M (1992) Immunocytochemical study of progesterone receptor in human meningioma. Acta Neurochir (Wien) 115: 20–30Google Scholar
  31. 31.
    Poisson M, Pertuiset BF, Mognilewsky M, Magdelenat H, Martin PM (1984) Steroid hormone receptors in the central nervous system. Rev Neurol 140: 233–248PubMedGoogle Scholar
  32. 32.
    Rachlin JR, Rosenblum ML (1991) Etiology and biology of meningiomas. In: Al-Mefty O (ed) Meningiomas. Raven, New York, pp 27–35Google Scholar
  33. 33.
    Reubi JC, Cortes R, Maurer R, Probst A, Palacios JM (1986) Distribution of somatostatin receptors in the human brain: an autoradiographic study. Neuroscience 18: 329–346PubMedGoogle Scholar
  34. 34.
    Reubi JC, Maurer R, Klijn JGM, Stefanko SZ, Foekens JA Blaauw G, Blankenstein MA, Lamberts SWJ (1986) High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab 63: 433–438PubMedGoogle Scholar
  35. 35.
    Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SWJ (1987) Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 47: 5758–5764PubMedGoogle Scholar
  36. 36.
    Reubi JC, Kvols L, Krenning E, Lamberts SWJ (1990) Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 39: 78–81PubMedGoogle Scholar
  37. 37.
    Reubi JC, Waser B, Khosla S, Kvols L, Gowellner JR, Krenning E, Lamberts S (1992) In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 74: 1082–1089PubMedGoogle Scholar
  38. 38.
    Rosseou G, Mark A, Davis DO (1991) Gd-DTPA-Enhancement magnetic resonance imaging of the cavernous sinus. Acta Neurochir (Wien) [Suppl] 53: 113–116Google Scholar
  39. 39.
    Rünzi HW, Jaspers C, Windeck R, Benker G, Mehdorn HM, Reinhardt V, Reinwein D (1989) Successful treatment of meningioma with octreotide. Letter to the editor. Lancet i: 1074Google Scholar
  40. 40.
    Samii M, Ammirati M, Makran A, Bini W, Sepehrnia A (1989) Surgery of petroclival meningiomas: report of 24 cases. Neurosurgery 24: 12–17PubMedGoogle Scholar
  41. 41.
    Schrell UMH, Fahlbusch R, Adams EF, Nomikos P, Reif M (1990) Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors. J Clin Endocrinol Metab 71: 1669–1671PubMedGoogle Scholar
  42. 42.
    Schrell UMH, Fahlbusch R (1991) Hormonal manipulation of cerebral meningiomas. In: Al-Mefty O (ed) Meningiomas. Raven, New York, pp 273–283Google Scholar
  43. 43.
    Schrell UMH, Nomikos P, Fahlbusch R (1992) Serotonin (5-HT2) receptors in human cerebral meningioma tissue. Ninth International Congress of Endocrinology, Nice, August 30–September 5, 1992, Abstract P-19.04.086, Abstract bookGoogle Scholar
  44. 44.
    Schrell UMH, Nomikos P, Fahlbusch R (1992) Presence of dopamine d1 receptors and absence of dopamine D2 receptors in human cerebral meningioma tissue. J Neurosurg 77: 288–294PubMedGoogle Scholar
  45. 45.
    Schrell UMH, Fahlbusch R, Hren J (1992) Suramin inhibits growth of human cerebral meningiomas in culture. Ninth International Congress of Endocrinology, Nice, August 30–September 5, 1992, Abstract P-19.04.049, Abstract bookGoogle Scholar
  46. 46.
    Shekar LN, Pomeranz Sh, Sen ChN (1991) Management of tumours involving the cavernous sinus. Acta Neurochir (Wien) [Suppl] 53: 101–112Google Scholar
  47. 47.
    Shotton JC, Kuhwoede R, Fisch U (1992) Messenchymal tumors of the skull base with particular reference to surgical management and outcome. Skull Base Surg 2: 112–117Google Scholar
  48. 48.
    Spetzler R, Daspit CP, Pappas CTE (1992) The combined supraand infratentorial approach for lesions of the petrous and clival regions: experience with 46 cases. J Neurosurg 76: 588–599PubMedGoogle Scholar
  49. 49.
    Ur E, Mather J, Bomanji J, Ellison D, Britton KE, Grossmann AB, Wass JAH, Besser GM (1992) Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clin Endocrinol 36: 147–150Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • G. Hildebrandt
    • 1
  • K. Scheidhauer
    • 2
  • C. Luyken
    • 1
  • H. Schicha
    • 2
  • N. Klug
    • 1
  • P. Dahms
    • 3
  • B. Krisch
    • 3
  1. 1.Department of NeurosurgeryUniversity of KölnKöln
  2. 2.Department of Nuclear MedicineUniversity of KölnKöln
  3. 3.Department of AnatomyUniversity of KielKielFederal Republic of Germany

Personalised recommendations